Shares of Krystal Biotech Inc. (KRYS) have now more than doubled in value since touching a 52-week low of $22.02 on June 14, 2019.
Krystal Biotech is a clinical-stage gene therapy company developing topical and intradermal novel treatments for patients suffering from rare dermatological diseases and chronic skin diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com